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Imaging for radiotherapy is indicated during all phases
of diagnosis and treatment: for staging, radiotherapy
planning, therapy response monitoring and prediction,
follow-up and relapse detection. Besides conventional
CT imaging, functional (e.g. MRI) and molecular (e.g.
PET) imaging modalities are increasingly used in
patients before, during and after radiotherapy.
Staging and radiotherapy planning
Given the limitations of CT for adequate detection of
lesions in many tumor types, functional and molecular
imaging is used for improved detection of lesions and
assessment of loco-regional disease that should be
included in the radiation treatment plan [1,2]. This may
result in an increase as well as a decrease of the gross
tumor volume (GTV). Increasing the GTV with lesions
suspicious of malignancy enhances the likelihood of
optimal tumor control. Conversely, exclusion of lesions
detected on CT, but with a low likelihood of malignancy
on MRI or PET decreases the GTV and thus the side
effects associated with larger fields while maintaining
optimal loco-regional control of the cancer [3].
Therapy response prediction and monitoring
In case radiotherapy is indicated after previous systemic
therapy (e.g. in malignant lymphoma), molecular imaging
is increasingly used to assess areas of viable tumor, which
may prevent the need to irradiate large areas of residual
abnormalities which contain no viable tumor [4].
Furthermore, adaptation of treatment during radiother-
apy (before the full radiation dose has been administered)
offers the chance to increase the dose to radioresistant
areas in solid tumor, while the dose to areas that respond
very well may be decreased [5]. The clinical impact of this
paradigm is currently the subject of many clinical trials,
which will make radiation therapy a much more dynamic
treatment by a more or less continuous evaluation of
tumors by functional and molecular imaging and subse-
quent adaptation of radiotherapy plans. This concept will
be largely facilitated by the use of MRI-Linac and maybe
in future PET-Linac.
Follow-up and relapse detection
In case of suspicion of relapse, advanced imaging may pre-
select those patients who are potentially eligible for salvage
therapy, but require invasive diagnostic procedures to
establish a histological diagnosis. With an increasing num-
ber of local and systemic treatment options becoming
available for many tumor types, the demands for optimal
follow-up becomes increasingly important [6]. The choice
for the optimal imaging modality and the timing of ima-
ging are crucial for adequately restaging patients. The
impact of radiotherapy-related effects such as radiation-
induced inflammation and fibrosis on the accuracy of ima-
ging procedures has to be considered. When considering
imaging during follow-up of patients, the clinical need for
early detection and the availability of meaningful subse-
quent treatment should be weighed against the increasing
costs associated with the frequent use of advanced imaging
techniques (i.e. appropriate use).
Conclusions
Multimodal advanced functional and molecular imaging is
increasingly used before, during and after radiotherapy.
The evidence for many indications is rapidly evolving.
This offers great potential for optimized, individualized
treatment of patients, providing better chances for loco-
regional tumor control and less treatment-associated side
effects.
Published: 9 October 2014
References
1. MacManus MP, Hicks RJ: The role of positron emission tomography/
computed tomography in radiation therapy planning for patients with
lung cancer. Semin Nucl Med 2012, 42:308-319.
Correspondence: Wim.Oyen@Radboudumc.nl
Department of Radiology and Nuclear Medicine, Radboud University Medical
Center, Nijmegen, The Netherlands
Oyen Cancer Imaging 2014, 14(Suppl 1):O40
http://www.cancerimagingjournal.com/content/14/S1/O40
© 2014 Oyen; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
2. Meijer HJ, Debats OA, Th van Lin EN, van Vulpen M, Witjes JA, Oyen WJ,
Barentsz JO, Kaanders JH: Individualized image-based lymph node
irradiation for prostate cancer. Nat Rev Urol 2013, 10:376-385.
3. Nestle U, Weber W, Hentschel M, Grosu AL: Biological imaging in radiation
therapy: role of positron emission tomography. Phys Med Biol 2009, 54:
R1-25.
4. Hutchings M: How does PET/CT help in selecting therapy for patients
with Hodgkin lymphoma? Hematology Am Soc Hematol Educ Program
2012, 2012:322-327.
5. Hoeben BA, Bussink J, Troost EG, Oyen WJ, Kaanders JH: Molecular PET
imaging for biology-guided adaptive radiotherapy of head and neck
cancer. Acta Oncol 2013, 52:1257-1271.
6. Mak D, Corry J, Lau E, Rischin D, Hicks RJ: Role of FDG-PET/CT in staging
and follow-up of head and neck squamous cell carcinoma. Q J Nucl Med
Mol Imaging 2011, 55:487-499.
doi:10.1186/1470-7330-14-S1-O40
Cite this article as: Oyen: Contributions of multimodal imaging. Cancer
Imaging 2014 14(Suppl 1):O40.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Oyen Cancer Imaging 2014, 14(Suppl 1):O40
http://www.cancerimagingjournal.com/content/14/S1/O40
Page 2 of 2
